Program
sanritatug
Also written as “SG301 SC Injection”, “SG301 Injection” and “SG301”.
Its studies are mostly in Lupus Erythematosus, Systemic · Multiple Myeloma, led by Hangzhou Sumgen Biotech.
Furthest: phase 3, since Jul 5, 20245 company-led studies, 4 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Sumgen Biotech | 54 open or running | phase 3since Jul 5, 2024 | Dec 10, 2020 | Mar 31, 2027phase 2 · NCT07764627 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2020First study: phase 1 study in RecurrenceFirst studyNCT04684108 · 61 enrolled · China
- Nov 13, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT06144710 · 48 enrolled · China
- Jul 5, 2024Phase 3 study in Multiple MyelomaNCT06508983 · 360 planned · China
- Feb 25, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07447986 · 120 planned · China
- Aug 10, 2026Phase 2 study in Antibody Mediated RejectionNCT07764627 · 10 planned · China
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Antibody Mediated RejectionNCT07764627
- Mar 31, 2027Primary completion: phase 3 study in Multiple MyelomaNCT06508983
- Sep 30, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07447986
TargetBeta
CD38 →read by rule
“A human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that targets the cell surface glycoprotein CD38, ”NCIt, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07764627Antibody Mediated Rejection · China | 2 | Not yet recruiting | Mar 31, 2027 | 10 |
| NCT07447986Lupus Erythematosus, Systemic · China | 2 | Recruiting | Sep 30, 2027 | 120 |
| NCT06508983Multiple Myeloma · China | 3 | Recruiting | Mar 31, 2027 | 360 |
| NCT06144710Lupus Erythematosus, Systemic · China | 1 | Completed | Jan 7, 2026 | 48 |
| NCT04684108Recurrence · China | 1 | Active, not recruiting | Jun 30, 2024 | 61 |
How it is read
Names in the registry
- “SG301 SC Injection”, 3 entries
- “SG301 Injection”, 2 entries
- “SG301”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Multiple Myeloma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.